专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2009140572A2 COMBINATORIAL TREATMENT WITH GLUCOSE REGULATED PROTEIN-170 AND MELANOMA DIFFERENTIATION ASSOCIATED GENE-7 审中-公开
标题翻译：用葡萄糖调节蛋白-170和相关蛋白质差异的基因组合7的组合治疗
公开(公告)号：WO2009140572A2
公开(公告)日：2009-11-19
申请号：PCT/US2009044092
申请日：2009-05-15
申请人： UNIV COLUMBIA , FISHER PAUL B , WANG XIANG-YANG
发明人： FISHER PAUL B , WANG XIANG-YANG
IPC分类号： A61K48/00
CPC分类号： C07K14/4702 , A61K48/005 , A61K48/0083 , C07K14/47 , C07K2319/02 , C12N2799/022 , C12N2799/04
摘要： The present invention relates to methods of treating cancer comprising administering, to a subject in need of such treatment, an effective amount of a combination of a GRP- 170 and a MDA-7 molecule. The combined use of these agents allows effective therapy of cancers that may be relatively resistant to either agent alone.
摘要翻译：本发明涉及治疗癌症的方法，包括向需要这种治疗的受试者施用有效量的GRP-170和MDA-7分子的组合。这些药物的组合使用可以有效治疗可能相对单独使用任一药物的癌症。

12. 发明申请

WO2008063773A3 COMBINATORIAL TREATMENT WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR MOLECULES AND MELANOMA DIFFERENTIATION ASSOCIATED GENE-7 审中-公开
标题翻译：表皮生长因子受体抑制剂分子与黑色素瘤分化相关基因7的组合治疗
公开(公告)号：WO2008063773A3
公开(公告)日：2008-10-02
申请号：PCT/US2007080962
申请日：2007-10-10
申请人： UNIV COLUMBIA , SETTLEMAN JEFFREY , FISHER PAUL B , EMDAD LUNI
发明人： SETTLEMAN JEFFREY , FISHER PAUL B , EMDAD LUNI
IPC分类号： A01N63/00
CPC分类号： A61K31/7088 , A61K38/179 , A61K38/20 , A61K45/06 , A61K48/00 , C12N15/86 , C12N2710/10343 , A61K2300/00
摘要： The present invention relates to methods of treating a cancer associated with aberrant EGFR-activity comprising administering, to a subject in need of such treatment, an effective amount of a combination of an EGFR inhibitor and a MD A-7 molecule. The combined use of these agents allows effective therapy of cancers that may be relatively resistant to either agent alone.
摘要翻译：本发明涉及治疗与异常EGFR活性相关的癌症的方法，其包括向需要这种治疗的受试者施用有效量的EGFR抑制剂和MD A-7分子的组合。这些药物的联合使用允许有效治疗对任一药剂可能相对具有抗性的癌症。

13. 发明申请

WO2006042223A2 OLD-35 AS AN INFLAMMATORY AGENT 审中-公开
标题翻译： OLD-35作为炎症药剂
公开(公告)号：WO2006042223A2
公开(公告)日：2006-04-20
申请号：PCT/US2005036409
申请日：2005-10-07
申请人： UNIV COLUMBIA , FISHER PAUL B , SARKAR DEVANAND
发明人： FISHER PAUL B , SARKAR DEVANAND
IPC分类号： A01K67/027
CPC分类号： C12Q1/48 , A01K2267/03 , A61K38/00 , A61K2039/505 , C07K14/47 , C07K16/40 , G01N33/5023 , G01N33/5088 , G01N33/6893 , G01N2500/00 , Y10T436/143333
摘要： The present invention relates to the discovery that OLD-35, at least in part through the generation of reactive oxygen species, induces a number of inflammatory cytokines and promotes nuclear translocation and binding of the transcriptional activator NF-?B. Accordingly, the present invention provides for assay systems (which either utilize the old-35 promoter or the old-35 gene) that may be used to identify new anti-inflammatory agents; model systems of inflammation based on over-expression of the old-35 gene in cells and tissues (including specific model systems for arthritis, atherosclerosis and Alzheimer's disease); methods and kits for diagnosing old-35 associated inflammatory conditions, and methods of treatment and anti-inflammatory compositions that utilize agents that antagonize OLD-35 activity.
摘要翻译：本发明涉及至少部分通过产生活性氧的OLD-35诱导许多炎性细胞因子并促进转录激活因子NF-κB的核易位和结合。因此，本发明提供了可用于鉴定新的抗炎剂的测定系统（其使用老35启动子或旧-35基因）; 基于老35基因在细胞和组织（包括关节炎，动脉粥样硬化和阿尔茨海默氏病的特定模型系统）中过度表达的炎症模型系统; 用于诊断旧35相关炎症病症的方法和试剂盒，以及利用拮抗OLD-35活性的药物的治疗方法和抗炎组合物。

14. 发明申请

WO2004072253A3 HUMAN EXCITATORY AMINO ACID TRANSPORTER-2 GENE PROMOTER AND USES THEREOF 审中-公开
标题翻译：人类激素氨基酸转运蛋白-2基因启动子及其用途
公开(公告)号：WO2004072253A3
公开(公告)日：2005-10-13
申请号：PCT/US2004003700
申请日：2004-02-09
申请人： UNIV COLUMBIA , FISHER PAUL B , SU ZAO-ZHONG
发明人： FISHER PAUL B , SU ZAO-ZHONG
IPC分类号： A61K31/711 , A61K48/00 , C07H21/02 , C07H21/04 , C07K14/705 , C12N20060101 , C12N5/10 , C12N15/63 , C12N15/85 , C12Q1/02 , C12Q1/68
CPC分类号： C07K14/705
摘要： The nucleic acid sequence of the human Excitatory Amino Acid Transporter-2 Gene (hEAAT2) promoter, a nucleic acid sequence that hybridizes to the hEAAT2 promoter nucleic acid sequence under stringent hybridization conditions, and a nucleic acid sequence that is functionally equivalent to the hEAAT2 promoter sequence are provided, as are vectors containing these nucleic acid sequences. In addition, methods for the use of these nucleic acids to achieve tissue- or cell-specific gene expression are provided, as are methods for the use of these hEAAT2 promoter nucleic acids to identify agents that can modulate glutamate transport or the activity of the glutamate promoter. Such agents may be useful in the prevention, palliation or treatment of neurodegenerative and/or cerebrovascular diseases.
摘要翻译：人激动性氨基酸转运蛋白-2基因（hEAAT2）启动子的核酸序列，在严格杂交条件下与hEAAT2启动子核酸序列杂交的核酸序列以及在功能上等同于hEAAT2启动子的核酸序列提供了序列，以及含有这些核酸序列的载体。此外，提供了使用这些核酸实现组织或细胞特异性基因表达的方法，以及使用这些hEAAT2启动子核酸鉴定可调节谷氨酸转运或谷氨酸活性的试剂的方法子。这样的药剂可用于预防，缓解或治疗神经变性和/或脑血管疾病。

15. 发明申请

WO0216419A3 PROGRESSION SUPPRESSED GENE 13 (PSGEN 13) AND USES THEREOF 审中-公开
标题翻译：进行抑制基因13（PSGEN 13）及其用途
公开(公告)号：WO0216419A3
公开(公告)日：2002-10-10
申请号：PCT/US0126795
申请日：2001-08-27
申请人： UNIV COLUMBIA , FISHER PAUL B , KANG DONG-CHUL , SU ZAO-ZHONG
发明人： FISHER PAUL B , KANG DONG-CHUL , SU ZAO-ZHONG
IPC分类号： G01N33/53 , A61K38/00 , A61K48/00 , A61P9/00 , A61P35/00 , A61P35/02 , C07K14/47 , C07K16/18 , C12N5/06 , C12N5/10 , C12N15/09 , C12Q1/68 , G01N33/566 , G01N33/574 , C12N15/00
CPC分类号： C07K14/4703 , A61K38/00
摘要： The invention provides for isolated nucleic acids encoding Progression Suppressed Gene 13 (PS Gen 13) proteins, vectors comprising said nucleic acids, isolated PSGen 13 proteins, and methods of using such molecules to prevent the growth of cancer cells and/or new blood vessels and accordingly to treat patients suffering from cancer. It is based, at least in part, on the characterization of the complete cDNAs encoding rat and human PSGen 13, and on the discovery that increased levels of PSGen 13 expression can suppress the transformed phenotype and inhibit the activities of promoter elements associated with cancer progression and angiogenesis. In various embodiments, the present invention provides a method for inhibiting growth of a cancer cell which comprises contacting the cancer cell with a nucleic acid encoding a PSGen 13 protein, a PSGen 13 protein or a PSGen 13 activator compound in a sufficient amount so as to inhibit growth of the cancer cell. The invention also provides a method for treating cancer in a subject which comprises contacting a cell of the subject with a nucleic acid encoding a PSGen 13 protein in a sufficient amount so as to cause the cell to express the PSGen 13 protein, thereby treating cancer in the subject.
摘要翻译：本发明提供了编码进展抑制基因13（PS Gen 13）蛋白的分离核酸，包含所述核酸的载体，分离的PSGen 13蛋白，以及使用这些分子来防止癌细胞和/或新血管生长的方法，以及因此治疗癌症患者。至少部分基于编码大鼠和人类PSGen13的完整cDNAs的表征，并且发现增加的PSGen13表达水平可以抑制转化的表型并抑制与癌症进展相关的启动子元件的活性和血管发生。在各种实施方案中，本发明提供了抑制癌细胞生长的方法，其包括将足够量的癌细胞与编码PSGen13蛋白，PSGen13蛋白或PSGen13激活剂化合物的核酸接触，以便抑制癌细胞的生长。本发明还提供了一种治疗受试者的癌症的方法，其包括将受试者的细胞与编码PSGen 13蛋白的核酸充分接触，以使细胞表达PSGen13蛋白，从而治疗癌症主题。

16. 发明申请

WO0046391A2 GENES DISPLAYING ENHANCED EXPRESSION DURING CELLULAR SENESCENCE AND TERMINAL CELL DIFFERENTIATION AND USES THEREOF 审中-公开
标题翻译：在细胞感染和终末细胞分化期间显示增强表达的基因及其用途
公开(公告)号：WO0046391A2
公开(公告)日：2000-08-10
申请号：PCT/US0002920
申请日：2000-02-02
申请人： UNIV COLUMBIA , FISHER PAUL B , LESZCYNIECKA MAGDALENA
发明人： FISHER PAUL B , LESZCYNIECKA MAGDALENA
IPC分类号： G01N33/50 , A61K31/7105 , A61K31/711 , A61K35/76 , A61K38/00 , A61K45/00 , A61K48/00 , A61P9/14 , A61P17/06 , A61P35/00 , A61P35/02 , A61P37/00 , A61P43/00 , C07K14/315 , C07K14/47 , C07K16/18 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/74 , C12P21/02 , C12P21/08 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566 , C12Q
CPC分类号： C07K14/47 , C07K14/315 , C07K14/82 , C12N15/746
摘要： This invention provides isolated nucleic acid molecules encoding an OLD-35 protein, OLD-64 protein, OLD-137 protein, OLD-139 protein, OLD-142 protein or OLD-175 protein. This invention further provides a purified OLD-35 protein, OLD-64, OLD-137, OLD-139, OLD-142 and OLD-175. Finally, this invention provides different uses of the nucleic acids and proteins.
摘要翻译：本发明提供编码OLD-35蛋白，OLD-64蛋白，OLD-137蛋白，OLD-139蛋白，OLD-142蛋白或OLD-175蛋白的分离的核酸分子。本发明还提供了纯化的OLD-35蛋白，OLD-64，OLD-137，OLD-139，OLD-142和OLD-175。最后，本发明提供了核酸和蛋白质的不同用途。

17. 发明申请

WO2008073615A4 N-GLYCOSYLATION MUTANT OF MELANOMA DIFFERENTIATION ASSOCIATED GENE-7 审中-公开
标题翻译： MELANOMA差异相关基因-7的N-糖苷化突变体
公开(公告)号：WO2008073615A4
公开(公告)日：2009-02-19
申请号：PCT/US2007083491
申请日：2007-11-02
申请人： UNIV COLUMBIA , GOPALKRISHNAN RAHUL V , SAUANE MOIRA , FISHER PAUL B
发明人： GOPALKRISHNAN RAHUL V , SAUANE MOIRA , FISHER PAUL B
IPC分类号： C07H21/04 , A61K39/00 , C07H21/02 , C07K14/00 , C12N15/11
CPC分类号： C07K14/47 , A61K38/00
摘要： The present invention relates to MDA-7 variant proteins which are deficient in or lack glycosylation. It is based, at least in part, on the results of experiments which have demonstrated that such variants are functionally equivalent to wild-type MDA-7 protein. Such proteins may be more easily produced large-scale than the wild-type protein, and may be found to be less immunogenic (thereby facilitating treatment, especially repeated treatments). Accordingly, the present invention provides for such proteins ("Gly(def)MDA-7 proteins"), nucleic acids encoding them ("Gly(def)mda-7 nucleic acids), pharmaceutical compositions comprising such proteins or nucleic acids, and related methods of treatment.
摘要翻译：本发明涉及缺乏或缺乏糖基化的MDA-7变体蛋白质。至少部分基于实验结果，已经证明这些变体在功能上等同于野生型MDA-7蛋白。这样的蛋白质可能比野生型蛋白质更容易产生，并且可以发现其免疫原性较小（从而便于治疗，特别是重复治疗）。因此，本发明提供了这样的蛋白质（“Gly（def）MDA-7蛋白质”），编码它们的核酸（“Gly（def）mda-7核酸”），包含这种蛋白质或核酸的药物组合物，以及相关的治疗方法

18. 发明申请

WO2008073615A9 N-GLYCOSYLATION MUTANT OF MELANOMA DIFFERENTIATION ASSOCIATED GENE-7 审中-公开
标题翻译： MELANOMA差异相关基因-7的N-糖苷化突变体
公开(公告)号：WO2008073615A9
公开(公告)日：2008-12-24
申请号：PCT/US2007083491
申请日：2007-11-02
申请人： UNIV COLUMBIA , GOPALKRISHNAN RAHUL V , SAUANE MOIRA , FISHER PAUL B
发明人： GOPALKRISHNAN RAHUL V , SAUANE MOIRA , FISHER PAUL B
IPC分类号： C07H21/04 , A61K39/00 , C07H21/02 , C07K14/00 , C12N15/11
CPC分类号： C07K14/47 , A61K38/00
摘要： The present invention relates to MDA-7 variant proteins which are deficient in or lack glycosylation. It is based, at least in part, on the results of experiments which have demonstrated that such variants are functionally equivalent to wild-type MDA-7 protein. Such proteins may be more easily produced large-scale than the wild-type protein, and may be found to be less immunogenic (thereby facilitating treatment, especially repeated treatments). Accordingly, the present invention provides for such proteins ("Gly(def)MDA-7 proteins"), nucleic acids encoding them ("Gly(def)mda-7 nucleic acids), pharmaceutical compositions comprising such proteins or nucleic acids, and related methods of treatment.
摘要翻译：本发明涉及缺乏或缺乏糖基化的MDA-7变体蛋白质。至少部分基于实验结果，已经证明这些变体在功能上等同于野生型MDA-7蛋白。这样的蛋白质可能比野生型蛋白质更容易产生，并且可以发现其免疫原性较小（从而便于治疗，特别是重复治疗）。因此，本发明提供了这样的蛋白质（“Gly（def）MDA-7蛋白质”），编码它们的核酸（“Gly（def）mda-7核酸”），包含这种蛋白质或核酸的药物组合物，以及相关的治疗方法

19. 发明申请

WO2008073615A2 N-GLYCOSYLATION MUTANT OF MELANOMA DIFFERENTIATION ASSOCIATED GENE-7 审中-公开
公开(公告)号：WO2008073615A2
公开(公告)日：2008-06-19
申请号：PCT/US2007083491
申请日：2007-11-02
申请人： UNIV COLUMBIA , GOPALKRISHNAN RAHUL V , SAUANE MOIRA , FISHER PAUL B
发明人： GOPALKRISHNAN RAHUL V , SAUANE MOIRA , FISHER PAUL B
IPC分类号： A61K38/17
CPC分类号： C07K14/47 , A61K38/00
摘要： The present invention relates to MDA-7 variant proteins which are deficient in or lack glycosylation. It is based, at least in part, on the results of experiments which have demonstrated that such variants are functionally equivalent to wild-type MDA-7 protein. Such proteins may be more easily produced large-scale than the wild-type protein, and may be found to be less immunogenic (thereby facilitating treatment, especially repeated treatments). Accordingly, the present invention provides for such proteins ("Gly(def)MDA-7 proteins"), nucleic acids encoding them ("Gly(def)mda-7 nucleic acids), pharmaceutical compositions comprising such proteins or nucleic acids, and related methods of treatment.

20. 发明申请

WO2006047311A3 CLONING OF THE RETINOIC ACID INDUCIBLE GENE-1 PROMOTER AND USES THEREOF 审中-公开
标题翻译：赖氨酸诱导基因-1启动子及其用途的克隆
公开(公告)号：WO2006047311A3
公开(公告)日：2006-09-14
申请号：PCT/US2005037950
申请日：2005-10-19
申请人： UNIV COLUMBIA , FISHER PAUL B , SU ZAO-ZHONG
发明人： FISHER PAUL B , SU ZAO-ZHONG
IPC分类号： C07H21/04 , A01K67/00 , C12N15/00 , C12Q1/02
CPC分类号： C07K14/47
摘要： The present invention relates to the human Retinoic Acid Inducible Gene-1 (hereafter, "RIG-1") promoter. The present invention provides for the promoter itself which is inducible by interferon, virus infection, retinoic acid and double-stranded RNA. A further embodiment includes expression constructs comprising the RIG-1 promoter operatively linked to a gene of interest, which may be a reporter gene or a therapeutic gene. It also provides for cells and non-human transgenic animals comprising such expression constructs. In addition, the present invention provides for methods of screening agents for anti-viral activity using RIG-1 promoter activation or inhibition as the basis of the screening system.
摘要翻译：本发明涉及人视黄酸诱导基因-1（以下称为“RIG-1”）启动子。本发明提供可由干扰素，病毒感染，视黄酸和双链RNA诱导的启动子本身。另一个实施方案包括包含可操作地连接到目的基因的RIG-1启动子的表达构建体，其可以是报道基因或治疗基因。它还提供包含这种表达构建体的细胞和非人转基因动物。此外，本发明提供了使用RIG-1启动子活化或抑制作为筛选系统的基础筛选抗病毒活性物质的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式